Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer
Autor: | Shunichi Yamashita, Valeri Krylov, Igor K. Khvostunov, Vladimir Saenko, Andrei Rodichev |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Biophysics Urology 030218 nuclear medicine & medical imaging Iodine Radioisotopes 03 medical and health sciences 0302 clinical medicine Biodosimetry medicine Humans Lymphocytes Thyroid Neoplasms Child Radiometry Adverse effect Thyroid cancer Aged General Environmental Science Chromosome Aberrations Radiation business.industry Cumulative dose Thyroid Dose-Response Relationship Radiation Radioiodine therapy Middle Aged medicine.disease Peripheral blood medicine.anatomical_structure 030220 oncology & carcinogenesis Female business Nuclear medicine Dose rate |
Zdroj: | Radiation and Environmental Biophysics. 56:213-226 |
ISSN: | 1432-2099 0301-634X |
DOI: | 10.1007/s00411-017-0696-3 |
Popis: | This study set out to investigate chromosomal damage in peripheral blood lymphocytes of thyroid cancer patients receiving 131I for thyroid remnant ablation or treatment of metastatic disease. The observed chromosomal damage was further converted to the estimates of whole-body dose to project the adverse side effects. Chromosomal aberration analysis was performed in 24 patients treated for the first time or after multiple courses. Blood samples were collected before treatment and 3 or 4 days after administration of 2–4 GBq of 131I. Both conventional cytogenetic and chromosome 2, 4 and 12 painting assays were used. To account for dose-rate effect, a dose-protraction factor was applied to calculate the whole-body dose. The mean dose was 0.62 Gy (95% CI: 0.44–0.77 Gy) in the subgroup of patients treated one time and 0.67 Gy (95% CI: 0.03–1.00 Gy) in re-treated patients. These dose estimates are about 1.7-fold higher than those disregarding the effect of exposure duration. In re-treated patients, the neglected dose-rate effect can result in underestimation of the cumulative whole-body dose by the factor ranging from 2.6 to 6.8. Elevated frequency of chromosomal aberrations observed in re-treated patients before radioiodine therapy allows estimation of a cumulative dose received from all previous treatments. |
Databáze: | OpenAIRE |
Externí odkaz: |